Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia is a research paper published in CHEST Journal (2022). On theSindex it has a DataRank of 0.483. It has been cited 24 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.483
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Heart, Lung, and Blood Institute
Grant: 10T2HL156812
National Heart, Lung, and Blood Institute
Grant: 42-312-0217571-66406L
NIGMS NIH HHS
Grant: T32 GM135169
NIGMS NIH HHS
Grant: K23 GM128005
NHLBI NIH HHS
Grant: OT2 HL156812
National Institutes of Health
Grant: 3OT2HL156812-01SD
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center
National Institutes of Health
University of Wisconsin-Madison
AbbVie
U.S. Department of Health and Human Services
Vanderbilt University Medical Center
Arog Pharmaceuticals
FWCI
2.72
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals